Business Context and Reporting Period
Insulet Corporation filed a Form 8-K on December 18, 2012, reporting the entry into a material definitive agreement. The filing concerns the Company's proprietary OmniPod Insulin Management System and its manufacturing relationship with Flextronics Marketing (L) Ltd.
Key Financial Metrics
This filing is a current report regarding a contractual agreement and does not contain financial statements. Consequently, specific values for revenue, profit, cash flow, margins, debt, or liquidity are not provided in this document.
Material Changes
The primary material change is the extension of the Manufacturing Services Agreement with Flextronics. Key terms of the Second Addendum include:
- Term Extension: The agreement term was extended until December 31, 2017, with provisions for automatic one-year renewals.
- Equipment Authorization: Flextronics is now authorized to purchase equipment necessary for the manufacture of Insulet's products during the agreement term.
- Pricing Structure: The agreement continues to operate on agreed-upon prices per unit based on a rolling 12-month forecast provided by Insulet.
Outlook, Risks, and Management Commentary
Management intends to submit a request for confidential treatment to the SEC to redact certain portions of the Addendum. The filing notes that the summary provided is qualified by reference to the full Original Agreement and the Addendum, which will be filed as exhibits to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012.
Investor Verification Checklist
- Verify the full text of the Second Addendum once filed as an exhibit to the 2012 Form 10-K to review redacted confidential terms.
- Confirm the specific pricing per unit and forecast mechanisms detailed in the Original Agreement.
- Monitor future 10-K filings for any financial impact related to the equipment purchases authorized under the Addendum.